Weight-Loss Drugs May Aid Brain Cancer Survival

Weight-loss injections, known as GLP-1 receptor agonists, are showing potential to extend survival for some advanced cancer patients whose disease has spread to the brain. These drugs, including those used for type 2 diabetes like Wegovy and Ozempic, may help patients with brain metastases live longer, according to a recent study.

The study, published in Jama Network Open, analyzed anonymized health records from over 19,000 patients diagnosed with cancer, type 2 diabetes, and brain metastases between 2018 and 2024. Researchers identified 866 patients treated with GLP-1 drugs and compared them to a matched group of 850 patients who did not receive these treatments.

Findings revealed that patients treated with GLP-1 drugs were approximately 37% less likely to die during a three-year follow-up period compared to those not on the medication. This survival advantage was observed across various cancer types, including lung, breast, and melanoma, and appeared consistent with different GLP-1 medications.

While the exact mechanisms are still under investigation, laboratory studies suggest GLP-1 drugs may protect brain cells and reduce inflammation. The research highlights that the potential benefits were observed specifically in patients who already had type 2 diabetes, emphasizing the need for individualized medical guidance from oncology and diabetes teams.